Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases including inflammatory bowel disease (IBD). Biosimilars are molecules highly similar to approved biologic medicines that have been developed to mitigate the high costs of biologics. Despite the fact that these therapies are tested to ensure non-inferiority to originator products, questions about appropriate use of biosiilars in IBD remain among clinicians and patients alike.
In this CME Outfitters webcast, expert faculty will focus on identifying key terminology related to biosimilar products, assessing evidence regarding the efficacy and safety of biosimilars in IBD, and improving patient-provider communication patterns on the topic of biosimilars.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
This activity is supported by educational funding provided by Amgen.
Gastroenterologists, PAs, nurse practitioners, nurses, pharmacists.
It is the policy of AGA and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Ha reports that she receives grant support from Pfizer Inc. She receives research support from Eli Lilly and Company and Pfizer Inc. She is on the advisory board for AbbVie Inc.; Eli Lilly and Company; Ferring Pharmaceuticals; Genentech, Inc.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc; Pfizer Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-109-H01-P.
Call us at 877.CME.PROS (877.263.7767).